Schizophreniform catatonia on 6 cases secondary to hydrocephalus with subthalamic mesencephalic tumor associated with hypodopaminergia

Neuropsychobiology

Volumn 34, Issue 2, 1996, Pages 76-81

  Neuman, Eric ^a   Rancurel, Gerald ^b   Lecrubier, Yves ^b   Fohanno, Denis ^b   Boiler, François ^a  

^a CENTRE PAUL BROCA   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Hydrocephalus; Hypodopaminergia; Schizophreniform catatonia; Subthalamic mescencephalic tumor

Indexed keywords

DOPAMINE; NEUROTRANSMITTER;

ADULT; ARTICLE; BRAIN TUMOR; CATATONIA; CLINICAL ARTICLE; CLINICAL FEATURE; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HYDROCEPHALUS; INTRACRANIAL PRESSURE; LATERAL BRAIN VENTRICLE; MALE; MESENCEPHALON; NERVE CELL NETWORK; PRIORITY JOURNAL;

ADULT; BRAIN NEOPLASMS; CATATONIA; DOPAMINE; FEMALE; HUMANS; HYDROCEPHALUS; MALE; SCHIZOPHRENIA; THALAMUS;

EID: 0029756181     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119296     Document Type: Article

References (82)

1. Alpcrt M, Friedhoff AJ, Marcos AJ, Diamont F: Paradoxal reaction to /.-Dopa in schizophrenic patients, Am J Psychiatry 1978;35: 1329-1332.
2. Carlson A: Does dopamine have a role in schizophrenia? Biol Psychiatry 1978; 13.1:3-21.
3. Crow TJ, Johnstone EC, Deakin JFW: Dopamine and schizophrenia, Lancet 1976;2:563-566.
4. Mackay AV, Crow TJ: Positives and negatives schizophrenics symptoms and the role of dopamine, Br J Psychiatry 1980:137:379-386.
5. Bourgeois M, Laforgc E, Muyard J, Blayac J: Endorphincs et schizophrénie, Ann Méd Psychol 1980;138:112-119.
6. Chassing-Beyne JL: Schizophrénie et endor-phines: espoir ou utopie, Actual Psychiatr 1979;2:33-38.
7. Crow TJ: Molecular pathology of schizophrenia: More than one disease process? Br Med J 1980:1:66-68.
8. Winokur WG, Morrison J, Clancy J: The clinical and genetic distinction of hebephrenic and paranoid schizophrenia, J Nerv Ment Dis 1974:159:12-19.
9. Owen F, Crow TJ, Poulter M, Cross AJ, Largdrcn A, Riley GJ: Increase dopaminc-receptor sensitivity in schizophrenia, Lancet 1978:2:223-225.
10. Crow TJ, Johnstone EC: Characteristics of patients with schizophrenia or neurological disorders and virus-like agent inCSF, Lancet 1979;1: 842-844.
11. Penn H, Racv J, Lapham L: Catatonic behavior, viral encephalopathy, and death, Arch Gen Psychiatry 1972:27:757-761.
12. Rancurcl G, Guedcncy A: Troubles mentaux au cours des encéphalites virales, Paris, Encyclopédie Médico-Chirurgicale, Editions Techniques, 1986, A10,9,20.
13. Baruk H: Lcscatatonicsttoxi-infectieuses, données cliniques, expérimentales et thérapeutiques, Encéphale 1930:25:2.
14. Gelenberg AJ, Mandel MR: Catatonie reactions to high-potency neuroleptic drugs, Arch Gen Psychiatry 1977;34:947-950.
15. Hockaday TE, Keynes WM, McKenzie JK: Catatonic stupor in elderly woman with hyperparathyroidism, Br Med J 1966;1:85-87.
16. Lishman WA: Organic Psychiatry-The Psychological Consequences of Cerebral Disorders, ed 2, Oxford, Blackwell, 1987.
17. Andreasen N, Nasrallah HA, Dunn V, Olson SC, Ehrhardt JC, Grove WM, Coffman JA, Crosse» JHW: Structural abnormalities in the frontal system in schizophrenia: A magnetic resonance imaging study, Arch Gen Psychiatry 1986;43:136-144.
18. Kelsoe JR, Cadet JL, Pickar D, Weinberger DR: Quantitative neuroanatomy in schizophrenia: A controlled magnetic resonance imaging study, Arch Gen Psychiatry 1988:45: 533-541.
19. Morihisa JM, McAnulty GE: Structure and function: Brain electrical activity mapping and computed tomography in schizophrenia, Biol Psychiatry 1985:20:3-19.
20. Weinberger DR, Berman KF, Zee RF: Physiological dysfunction of dorsolateral prcfrontal cortex in schizophrenia: 1, Regional cerebral blood flow evidence, II, Role of neuroleptic treatment, attention and mental effort, Arch Gen Psychiatry 1986:43:114-134.
21. Bracha HS, Klcinman JE: Postmortem neuro-chemistry in schizophrenia, Psychiatr Clin North Am 1986:9,1:133-141.
22. Kovelman JA, Scheibel AB: Biological substrates of schizophrenia, Acta Neurol Scand 1986:73:1-32.
23. Kohn R, Lilly RB, Sokol MS, Malloy PF: Psychiatric presentations of intracranial cysts, J Neuropsychiatry Clin Neurosci 1989;1:60-66.
24. Stevens JR: Neuropathology of schizophrenia, Arch Gen Psychiatry 1982;39:1131-1139.
25. Coffman JA, Andreasen NC, Nasrallah HA: Left hemispheric density deficits in chronic schizophrenia, Biol Psychiatry 1984; 19:1237-1247.
26. Crow TJ, Frith CD, Johnstone EC: Schizophrenia and cerebral atrophy, Lancet 1980;1: 1129-1130.
27. Kleisl K: Schizophrenic symptoms and cerebral pathology, J Mcnt Sci 1960;106:246-255.
28. Coffman JA, Mefferd J, Golden CJ, Bloch S, Graber B: Cerebellar atrophy in chronic schizophrenia, Lancet 1981:1:666.
29. Lippmann S, Manshadi M, Baldwin H, Drasin G, Rice J: Cerebellar vermis dimensions on computerized tomographic scans and schizophrenic and bipolar patients, Am J Psychiatry 1982;139:667-668.
30. Weinberger DR, Kleinman JE, Luching DJ, Bigelow LB, Wyatt RJ: Cerebellar pathology in schizophrenia: A controlled post-mortem study, Am J Psychiatry 1980:137:359-361
31. Fisman M: The brain stem in psychosis, Br J Psychiatry 1973:126:414-422.
32. Trimble MR, Cummings JL: Neuropsychiatrie disturbances following brainstem lesions, Br J Psychiatry 1981:138:56-59.
33. Andrcascn NC, Smith MR, Jacoby CG, Den-nert JW, Olsen SA: Ventricular enlargement in schizophrenia: I: Definition and prevalence: II: Relationship to positives and negatives symptoms, Am J Psychiatry 1982:139:292-302.
34. Johnstone EC, Crow TJ, Frith CD, Husband J, Krcel L: Cerebral ventricular size and cognitive impairment in chronic schizophrenia, Lancet 1976;2:924-926.
35. Nasrallah HA, Jacoby CG, McCallcv-Whitters M, Kuperman S: Cerebral ventricular enlargement in subtypes of chronic schizophrenia, Arch Gen Psychiatry 1982:39:774-777.
36. Weinberger DR, Bigelow' CB, Kleinman JE, Rosenblatt JE, Wyatt RJ: Cerebral ventricular enlargement in chronic schizophrenia on association with poor response to treatment, Arch Gen Psychiatry 1980:37:11-13.
37. Kan R, Mory Y, Suzuku S, Ono T, Takahashi Y, Kumashiro H: A case of temporal lobe astrocytoma associated with epileptic seizures and schizophrenia-like psychosis, Jpn J Psychiatr Neurol 1989:43:97-103.
38. Contamin F, Escourolle R, Nick J, Mignot B: Atrophie pallido-nigro-luysicnnc, syndrome akinctiquc avec pallilalie, rigidité opposition-nelle et catatonie, Rev Neurol (Paris) 1971; 124:107-120.
39. Laplanc D, Baulac M, Widlocher D, Dubois B: Pure psychic akinesia with bilateral lesions of basal ganglia, J Neurol Neurosurg Psychiatry 1984:47:377-385.
40. Klawans HL, Goetz C, Westheimcr R: Pathophysiology of schizophrenia and the striatum, DisNerv’Syst 1972:33:711-719.
41. Lidsky TL Weinhold PM, Levine FM: Implications of basal ganglionic dysfunction for schizophrenia, Biol Psychiatry 1979:14:3-12.
42. Furtado D, Freita A: Catatonic par compression dienccphalique, Rev Neurol 1946:78:499-500.
43. Levin S: Frontal lobe dysfunctions in schizophrenia: II, Impairments of psychological and brain functions, J Psychiatr Res 1984:18:57-72.
44. Shelton RC, Doran AR, Pickar D, Weinberger DR: Cerebral structural pathology in schizophrenia: Evidence fora selective prefrontal cortical defect, Am J Psychiatry 1987;1:15-23.
45. Andreasen NC: The concept of negative symptoms: Definition, specificity and significance, Psychiatry Psychobiol 1987:2/4:22-27.
46. Ariel RN, Golden CJ, Berg RA, Quaife MA, Dirkson JW, Forsell J, Wilson J, Graber B: Regional cerebral blood flow in schizophrenics: Tests using the xenon Xel33 inhalation method, Arch Gen Psychiatry 1983;40:258-263.
47. Mathew' R.I, Duncan GC, Weinman ML, Barr DL: Regional cerebral blood flow in schizophrenia, Arch Gen Psychiatry 1982:39:1121-1124.
48. Buchsbaum MS, de Lisi LE, Holcomb HH: Antero-posterior gradient in cerebral glucose (with positron tomography) use in schizophrenia and affective disorders, Arch Gen Psychiatry 1984:41:1159-1166.
49. Farkas T, Wolf AP, Jcagcr J: Regional brain glucose metabolism in chronic schizophrenia, Arch Gen Psychiatry 1984:41:293-300.
50. Cairns H, Oldfield RC, Penny Backer JB, Whiltcridgc D: Akinetic mutism with epidermoid cyst of the third ventricle, Brain 1941:64: 273.
51. Klee A: Akinetic mutism: Review of the literature and report of a case, J Nerv Ment Dis 1961:133:536.
52. DSM Ill-R: Manuel diagnostic et statistique des troubles mentaux, Paris, Masson, 1989
53. Ajuriagucrra J, Hecaen H, Jadoun R: Les troubles mentaux au cours des tumeurs de la région mésodicncéphalique, Encéphale 1954:5:406-478.
54. Burkle F-M, Lipowski Z-J: Colloid cvst of the third ventricle presenting as psychiatric disorders, Am J Psychiatry 1978;135:373-374.
55. Davison K, Bagley CR: Schizophrenia-like psychoses associated with organic disorders of the central nervous system: A review of the literature; in Herrington (ed): Curr Probl Neuropsychiatry, Ashford, Headley, 1969, vol4, pp 113-184.
56. de Morsier G: Trois cas de tumeur de septum du ventricule latéral à expression schizophréni-que, Encéphale 1968:57:187-193.
57. Messert B, Henke TK, Langherin W: Syndrome of akinetic mutism associated with obstructive hydrocephalus, Neurology 1966:16: 635-649.
58. Revelcy AM, Revclcy AR: Aqueduct stenosis and schizophrenia, J Neurol Neurosurg Psychiatry 1983:46:18-22.
59. Roberts JKA, Trimble MR, Robertson M: Schizophrenic psychosis associated with aqueduct stenosis in adults, J Neurol Neurosurg Psychiatry 1983:46:892-898.
60. Haug J: Pneumoenccphalographic studies in mental disease, Psychiat Scand 1962; 38(suppl): 1-114.
61. Johnstone EC, Crow TJ, Frith CD, Carney MWP: Mechanism of the antipsychotic effect in the treatment of acute schizophrenia, Lancet 1978;1:848-851.
62. Bannon MJ, Roth RH: Pharmacology of meso-cortical DA neurons, Pharmacol Rev 1983:35: 53-68.
63. Crow TJ, Deakin JFW, Largden A: The nucleus accumbens: Possible site of antipsychotic action of neuroleptics drugs? Psychol Méd 1977:7:213-221.
64. Heath RG: Correlation of brain function with emotional behavior, Biol Psychiatry 1976:11: 463-480.
65. Hôkfclt T, Ljungdatil A, Fuxc K, Johanson O: Dopamine nerve terminals in the rat limbic cortex, Aspects of the dopamine hypothesis of schizophrenia, Science 1974;184:177-179.
66. Lindvall O, Bjorklund A, Moore RY, Stenevi U: Mesencephalic dopamine neurons projecting to neocortex, Brain Res 1974:81:325-331.
67. Mesulam M: Principles of Behavioral Neurology, Philadelphia Davis, 1985.
68. Simon H, le Moal M: Influence des neurones dopamincrgiques du mésencéphale sur les processus d'attention et d'intention, Psychol Méd 1985:17:939-945.
69. Skultety FM: Behavioural effects of destructive lesions of pcri-aqueductal gray matter in adult cats, J Comp Neurol 1958; 110:337.
70. Angrist B, Pesclow E, Rubinstein M, Corwin J, Rotrosen J: Partial improvement in negative schizophrenic symptoms after amphetamine, Psychopharmacology 1982;78:128-130.
71. May RH: Catatonic-like states following phe-nothiazine therapy, Am J Psychiatry 1959:115: 1119-1120.
72. Pickar D, Brcicr A, Wokowitz OM, Pato C: Profiles of the pharmacologic response of positive and negative symptoms in schizophrenia, Psychiatry Psychobiol 1987:2/4:277-287.
73. Sayers AC, Handley SL: Catalepsy Induced by alpha-methyl tyrosine and (/-amphetamine: The role of catecholamine metabolism, Psycho-pharmacologia 1974:34:325-334.
74. Chouinard G, Jones BD: Schizophrenia as dopamine deficiency disease, Lancet 1978;2:99-100.
75. Lccrubier Y, Puech A, Simon P, Widlocher D: Schizophrénie: Hyper-ou hypofonctionnemcnt du système dopaminergique, Une hypothèse bipolaire, Psychol Méd 1980:2/12:2431-2441.
76. Glowinski J, Tassin JP, Thierry AM: The me-socortical prefrontal dopaminergic neurons, Trends Neurosci Res 1984;7:415-418.
77. Lewin RJ, Fogg L, Meitzer HY: Assessment of negative and positive symptoms in schizophrenia, Schizophr Bull 1983;9:368-378.
78. Meitzer HY, Stahl SM: The Dopamine hypothesis of schizophrenia: a review, Schizophr Bull 1976;2:19-76.
79. Snyder SR: The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor, Am J Psychiatry 1976:133:197-201.
80. Gerlach J, Luhdorf K: The effect of L-Dopa on young patients with simple schizophrenia treated with neuroleptic drugs a double blind crossover trial with modopar and placebo), Psychopharmacologia 1975:44:105-110.
81. Kay SR, Opler LA: L-Dopa in the treatment of negative schizophrenic symptoms: A single subject experimental study, Int J Psychiatry Med 1985-1986; 15:293-298.
82. Ross ED, Stewart RM: Akinetic mutism from hypothalamic damage: Successful treatment with dopamine agonists, Neurology 1981:31: 1435-1438.